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Suramin is a polysulfonated naphthylurea originally designed
as a treatment for trypanosomiasis; but that has also been
used to treat rodent models of fulminant hepatic failure and
focal brain ischemia. In this study, we determined the effects
of suramin on renal ischemia/reperfusion-induced acute
kidney injury in mice, in particular its effect when
administered after renal injury has been established.
Increasing concentrations of suramin were given 24 hours
following reperfusion, a time when serum creatinine levels
were at their highest level. This treatment improved renal
function, as evidenced by decreased blood urea nitrogen and
serum creatinine to control values and diminished
histopathologic tubular damage. Suramin-treated animals
had a significant reduction in apoptotic tubular cells and
infiltrating leukocytes. There was also an increase of
proliferating tubular cells following reperfusion compared to
the number found in untreated animals. Our study shows
that suramin promotes the recovery of renal function and has
effective therapeutic applications when given after the
occurrence of renal injury.
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Acute kidney injury (AKI) is a critical clinical problem with
mortality at approximately 50%.1 Renal ischemia/reperfusion
(I/R) is a common cause of AKI. Although several decades of
research have greatly improved our understanding of the
mechanisms underlying renal tubular cell injury and
death, and AKI, effective therapeutic interventions are still
unavailable.
The pathogenesis of AKI is complex and varies to some
extent based on the particular cause. Numerous studies have
demonstrated that renal tubular death and tubulointerstitial
inflammation are two important determinants of tissue
damage and renal failure.2,3 The proximal straight tubule in
the outer medulla of the kidney is particularly susceptible to
I/R injury. Damage to this segment is characterized initially
by the disruption of tight junctions.4 With more sustained
I/R, epithelial cells of the proximal tubule undergo necrotic
or apoptotic cell death.5 The acute inflammatory response
initiated by I/R is characterized by the generation of
proinflammatory chemokines and cytokines.3 Subsequently,
the postischemic tissue is invaded by many pro-inflammatory
leukocytes (neutrophils, macrophages, lymphocytes). These
leukocytes have been recognized as important contributors to
tissue damage through the release of oxygen-derived radicals
and production of cytokines.6
Epithelial cells that do not die participate in the
regeneration of tubular epithelium and the restoration of
renal function. During the recovery process, renal epithelial
cells dedifferentiate and then migrate and proliferate to
replace lost cells.7 Of those regenerative responses, prolifera-
tion is well studied in in vitro and in vivo systems. It has been
shown that various growth factors such as epidermal growth
factor, hepatocyte growth factor, and insulin-growth factor-1,
enhance renal proximal tubular cells (RPTC) proliferation
and accelerate the return of renal structure and function in
experimental models of AKI.1
Unfortunately, similar beneficial effects of insulin-growth
factor-1 were not observed in patients in clinical trials.8,9 In
one study, the patients did not develop acute renal failure,8
whereas in the other study the patients very sick, had
comorbid conditions, and there was a delay in insulin-growth
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factor-1 administration.9 Thus, whether agents that promote
regeneration of tubular epithelium are effective in humans is
unclear. Nevertheless, effective agents that can protect against
renal injury and/or promote renal regeneration are needed.
Recently, it was reported that pre- or coadministration of
suramin, a polysulfonated naphthylurea, protects the liver
from injury caused by D-galactosamine and lipopolysacchar-
ide in mice10 and reduces brain damage induced by ischemia
in rats.11 The mechanism by which suramin protects these
organs from injury remains incompletely understood, but
may be associated with inhibition of apoptosis, and
suppression of inflammatory cytokine production. Suramin
preincubation inhibited tumor-necrosis factor-a and inter-
leukin-6 production, tumor-necrosis factor-a and interleu-
kin-6 mRNA expression, and nuclear factor-kB activity in
macrophages12 and release of interleukin-6 and monocyte
chemoattractant protein-1 in human dermal endothelial
cells.13 In addition to these effects, we have shown that
suramin can promote renal proximal tubular cell prolifera-
tion and scattering in vitro.14 However, it is unknown
whether suramin is beneficial in AKI.
In this study, we examined the effect of suramin on renal
pathological changes and function in a murine model of
renal I/R-induced AKI. Because drug treatment to prevent
AKI is not usually possible, we examined the more relevant
question of whether suramin promoted the return of renal
function by administering suramin 24 h after I/R when
serum creatinine levels were maximal. Renal tissue damage
was assessed by measuring plasma blood urea nitrogen
(BUN) and serum creatinine and by changes in renal
histology. We also sought to determine the mechanism
underlying suramin effects by examining the effect of
suramin on apoptosis, leukocyte infiltration, and tubular cell
proliferation.
RESULTS
Suramin treatment decreases BUN and creatinine levels
Numerous agents protect against AKI when administered
before or at the time of reperfusion.15 A treatment would be
more clinically useful if it were effective when administrated
after ischemia. To determine whether delayed administration
of suramin promotes recovery of renal function in a murine
model of AKI, mice were administered a variety of doses of
suramin 24 h after release of the vascular clamps and
reestablishment of blood flow. As shown in Figure 1, mice
subjected to 26 min of renal I/R had significantly increased
serum creatinine and BUN levels at 24 h and remained at
these levels at 48 h after ischemic injury. Administration of
suramin at 24 h after I/R injury reduced both BUN and
creatinine levels compared with vehicle alone at 48 h after
ischemia (Figure 1). The improvement of renal functions by
suramin occurred in a dose-dependent manner with the
maximum and complete effect observed at 0.1–1 mg/kg.
Suramin at 10 mg/kg did not exhibit toxicity. These data reveal
that suramin promotes recovery from I/R-induced AKI.
Suramin treatment decreases histopathologic damage to
tubules
To determine if the surmain-induced functional changes were
associated with histological changes, histological changes
were examined 48 h after ischemia. Tubular dilatation,
swelling, necrosis, luminal congestion, and hemorrhage were
present in the kidneys of mice subjected to IR, but these
changes were decreased in animals treated with suramin
(Figure 2). Scoring of kidney sections for histopathologic
damage to the tubules showed that suramin at 1 mg/kg
decreased damage (Figure 2). Sham-operated mice incurred
no tubular injury. Thus, suramin treatment decreased renal
histological damage after I/R.
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Figure 1 | Effect of delayed administration of suramin on creatinine and BUN in mice subjected to I/R. (a, b) Mice were subjected to
26 min of bilateral renal ischemia and then allowed to recover for 24 or 48 h. (c, d) Five groups of mice were subjected to suramin (Sur)
treatment at 24 h after release of renal clamps at the indicated doses. Serum creatinine and BUN levels were measured. Data are shown as
means±s.d. Bars with different letters are significantly different from each other (Po0.05).
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Suramin treatment decreases apoptotic cell death in tubules
Apoptosis has been implicated in tubular damage after I/R
injury.2,3,5 We examined the effect of suramin on apoptosis
after I/R injury using the terminal deoxynucleotide transfer-
ase dUTP nick end labeling (TUNEL) assay. As shown in
Figure 3, animals with I/R injury displayed a greater number
of TUNEL-positive cells, predominantly in the tubules of the
outer medulla compared to tubules from sham-operated
controls. Some apoptotic cells were found in the tubular
lumen, indicating that cells detached from the tubular
basement membrane. In contrast, the kidneys from sura-
min-treated mice subjected to I/R displayed attenuated
apoptosis (Figure 3).
Caspase-3 is a critical protease that mediates apoptosis.5
To ensure the role of suramin in suppressing apoptosis after
I/R injury, we examined caspase-3 activation by staining
kidney tissue in situ using an antibody against active caspase-
3. An increase in the number of active caspase-3-positive
staining tubular cells was observed in injured kidney
(Figure 4). Suramin treatment significantly reduced this
population of tubular cells. Therefore, suramin attenuated
apoptosis after I/R injury.
Suramin reduces leukocyte infiltration
Leukocyte infiltration has been implicated as an important
cause of tissue injury in organs subjected to ischemia.3
We analyzed leukocyte infiltration in injured kidneys by
staining neutrophils and monocytes with naphthol AS-D
chloroacetate esterase. Prominent interstitial infiltration of
neutrophils and monocytes was observed at 48 h after
I/R (Figure 5). Treatment with suramin decreased leukocyte
infiltration.
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Figure 2 | Effect of delayed administration of suramin on renal
histology (hematoxylin and eosin). Mice were subjected to
26 min of bilateral renal ischemia, and then allowed to recover for
48 h. Suramin (Sur, 1 mg/kg) or vehicle (saline) was given 24 h after
release of renal clamps. (a) Sham; (b) I/Rþ saline; (c) I/Rþ suramin;
(d) tabulated data from scoring of renal tissue damage. Data are
shown as means±s.d. Bars with different superscript letters are
significantly different from each other (Po0.05). Original
magnification¼  100.
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Figure 3 | Effect of delayed administration of suramin on
apoptosis. Mice were subjected to I/R and treated with suramin
(Sur) as described in Figure 2. Representative photographs of the
distribution of TUNEL-positive nuclei in kidney of (a) sham,
(b) I/Rþ saline, and (c) suraminþ I/R-treated mice are shown. (d)
Tabulated data from tissue scoring. Data are shown as means±s.d.
Bars with different superscript letters are significantly different from
each other (Po0.05). Original magnification¼  200.
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Figure 4 | Effect of delayed administration of suramin on
caspase-3 activation. Mice were subjected to I/R and treated
with suramin (Sur) as described in Figure 2. Anticleaved caspase-3
antibody was used to stain the cells with cleaved caspase-3 in
kidney tissue section. (a) sham; (b) I/Rþ saline; (c) I/Rþ suramin;
(d) tabulated data for numbers of tubular cells with cleaved
caspase-3-positive staining. Data are shown as means±s.d. Bars
with different superscript letters are significantly different from
each other (Po0.05). Original magnification¼  200.
306 Kidney International (2009) 75, 304–311
o r i g i n a l a r t i c l e S Zhuang et al.: Suramin promotes recovery from acute kidney injury
Suramin enhances tubular cell proliferation
We next examined the effect of suramin on tubular cell
proliferation by evaluating proliferating cell nuclear antigen
(PCNA) or phospho-histone H3- (serine 10) positive staining
cells. Phosphorylation of histone H3 at serine 10 is necessary
for cell-cycle progression and can specifically mark cells
undergoing mitosis.16,17 As shown in Figure 6, whereas the
kidneys from I/R-treated animals displayed a small number
of PCNA-positive proximal tubule epithelial cells (5±0.8
cells/HPF), kidneys from suramin-treated mice subjected to
I/R displayed a twofold increase in proliferating tubular cells
(11±0.9 cells/HPF). Similarly, a small number of phospho-
histone H3-positive cells were observed in I/R-injured
animals, and the number of these cells increased in mice
subjected to I/R and treated with suramin (Figure 6). These
data are consistent with our previous observation that
suramin promotes renal tubular cell proliferation in primary
cultures of RPTC.14
Suramin, but not other P2 antagonists, promotes cell
proliferation in primary cultures of RPTC
If suramin exerts its proliferative effects in RPTC through the
blockade of P2 receptor signaling, other P2 receptor
antagonists should also induce proliferation in RPTC. To
test this hypothesis, RPTC were treated with suramin and
three other P2 receptor antagonists (reactive blue 2 (RB2),
pyridoxal-phosphate-6-azophenyl-20,40-disulfonate (PPADS),
and 20-deoxy-N6-methyladenosine 30,50-bisphosphate tetra-
ammonium (MRS2179)) for 48 h and the number of cells in
the S-phase of the cell cycle were measured with flow
cytometry. RB2 is a P2Y antagonist.18 PPADS is an antagonist
of P2Y and P2X receptors,19–21 and MRS2179 is a selective
P2Y1 receptor antagonist.
22 The concentrations used for each
antagonist have been reported to block P2 receptor-mediated
biological responses in other studies.23–25 In agreement with
Figure 5 | Effect of delayed administration of suramin on
leukocyte infiltration. Mice were subjected to I/R and treated
with suramin (Sur) as described in Figure 2. Naphthol AS-D
chloroacetate esterase kit was used to stain neutrophils and
monocytes in kidney sections of corticomedullary and medullary
areas of (a) sham-operated, (b) untreated, and (c) suramin-treated
mice, respectively. Infiltration of those cells, seen as deep-purple
dots, is more prominent in the injured kidney without suramin
treatment. Original magnification¼  200.
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Figure 6 | Effect of delayed administration of suramin on
tubular cell proliferation. Mice were subjected to I/R and treated
with suramin as described in Figure 2. Kidney sections were
stained with antibodies to (a) PCNA or (b) phospho-histone H3
(Ser 10). Tabulated data for numbers of tubular cells with (c)
positive PCNA or (d) phospho-histone H3 staining. Data are
shown as means±s.d. Bars with different letters are significantly
different from each other (Po0.05). Original magnification¼
 200.
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our previous results,14 suramin treatment led to a significant
increase in the number of cells in the S-phase of the cell cycle.
In contrast, treatment with RB2, PPADS, or MRS2179 did
not affect cell proliferation (Figure 7). These data reveal that
the biological events evoked by suramin are not shared by
other P2 receptor antagonists, suggesting that suramin
stimulates RPTC proliferation through a mechanism inde-
pendent of the P2 receptor.
DISCUSSION
Previous studies have shown that administration of numer-
ous agents before or at the time of I/R, drug, or toxicant
exposure attenuates AKI.15 Other studies indicate that
delayed administration of erythropoietin or a-melanocyte-
stimulating hormone up to 6 h after the onset of ischemia
protects against AKI.26,27 In addition, administration of an
antibody directed against intercellular adhesion molecule-1,
given 2 h after I/R blocked AKI in rats.28 However, no study
has shown that administration of an agent several hours after
an insult promotes return of renal function. Here, we
demonstrate that delayed administration of suramin for 24 h
after ischemia, when serum creatinine levels are maximal,
promoted recovery of renal function. This is of therapeutic
importance because most cases of acute renal failure in the
clinical setting are not identified until some time after the
insult has already occurred.
Promoting the return of renal function by late adminis-
tration of suramin suggests that suramin acts on those events
that occur after AKI and decreases renal function. It is known
that renal hemodynamics, tubular and endothelial injury, and
inflammatory processes contribute to the initial decrease of
renal function and/or maintenance of decreased renal
function.29 Although the mechanisms of recovery from AKI
and decreased renal function have received less attention,
dedifferentiation, proliferation, and redifferentiation of the
tubular epithelial cells and the reestablishment of an intact
polarized epithelium contribute to the recovery of renal
function. As such, suramin may promote the return of renal
function by controlling one or more of these pathological
processes.
Suramin may promote the return of renal function
through interference of late-onset apoptosis induced by I/R
injury. We found that suramin treatment attenuated tubular
damage and decreased the number of apoptotic cells in
injured kidneys. The mechanism by which suramin blocks
tubular cell apoptosis remains to be elucidated. Because
suramin was reported to inhibit apoptosis and liver damage
induced by CD95 stimulation and endotoxic shock mediated
by tumor-necrosis factor in mice,10 it is possible that suramin
exerts its antiapoptotic effect through blocking death
receptor activation in renal epithelial cells. In this context,
several reports pointed out that apoptosis of renal epithelial
cells is mediated by Fas and tumor-necrosis factor-a.30–33 On
the other hand, suramin may also inhibit cell death through
the mitochondrial apoptotic pathway. In support of this idea,
suramin blocked hydrogen peroxide-induced apoptosis in
human glioma (A172) cells.34 Hydrogen peroxide is pro-
duced during I/R injury35 and induces renal epithelial cell
death by mitochondrial dysfunction.36,37 In addition, we have
shown that suramin can activate Src and Akt, two important
signaling molecules that are associated with cell survival and
proliferation, and may mediate recovery of renal function
through this mechanism.14
Inflammation is an important mechanism in the initiation
and maintenance of renal damage.32,38 As a result of cell
injury and damage, intracellular molecules are released into
the extracellular space. Some of these molecules are cytokines
and chemokines, which can attract and activate leukocytes to
sites of injury and provoke an inflammatory response. The
presence of these leukocytes, particularly neutrophils, is
generally considered a damaging event, exacerbating I/R
damage.39 Leukocytes may contribute to AKI by potentiating
an inflammatory response that leads to the generation of
vasoconstricting agents, cytokines, and toxic mediators such
as reactive oxygen species and proteases.38 Neutrophil
infiltration begins within 4 h after the initiation of reperfu-
sion and peaks at 24 h, and large numbers of macrophages
infiltrate the renal interstitium at 24 h after reperfusion;40
therefore, reduction of renal neutrophil and macrophage
infiltration may decrease I/R renal injury. This hypothesis is
supported by our observation that delayed administration of
suramin reduced infiltration of leukocytes into the kidney
after renal I/R injury, suggesting another important mechan-
ism by which suramin may improve renal function.
A concern for administration of suramin in vivo is
whether it negatively regulates renal regeneration after I/R
injury as suramin is described as a mitogen inhibitor and has
been tested in the treatment of some cancers.41,42 In contrast
to this assumption, our data reveal that administration of
suramin-enhanced proliferation of proximal tubular cells in a
model of I/R-induced AKI. These data are consistent with an
earlier study that suramin induced kidney growth in rats,
predominantly in the proximal tubule without changes in the
glomeruli or medulla,43 and our recent observation that
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Figure 7 | Effect of P2 antagonists on proliferation of RPTC.
RPTC were cultured for 2 days and then incubated with suramin
(50mM), RB2 (100mM), PPADS (30 mM), or MRS2179 (10mM) for 48 h.
Cell proliferation was determined by measuring the number of
cells in S-phase of the cell cycle. Data are expressed as
means±s.e.m. (n¼ 3). Bars with different superscripts are
significantly different from each other (Po0.05).
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suramin stimulates proliferation of RPTC in primary
culture.14 Therefore, in addition to its reported antiproli-
ferative activity in some models, suramin stimulates cellular
proliferation in certain cell types including renal epithelial
cells. Although the mechanisms underlying suramin-stimu-
lated cell proliferation remain incompletely understood, we
suggest that antagonism of P2 receptors may not be involved
in this process because treatment of RPTC with suramin, but
not other purinergic P2 receptor antagonists, stimulated
RPTC proliferation. Suramin has multiple cellular effects and
we have previously demonstrated that inhibition of the Src-
PI3/Akt pathway partially blocks suramin-induced RPTC
proliferation,14 suggesting that the Src-PI3/Akt pathway
contributes to proliferation of this cell type in response to
suramin treatment.
Suramin has been used for the treatment of human
trypanosomiasis for more than 70 years and has been
evaluated for the treatment of certain tumors.44 Thus,
extensive data exist concerning its pharmacokinetics, efficacy,
and toxicity. Given the fact that the kidney can accumulate
suramin, which has a long half-life (21 days),45 the actual
concentrations of suramin accumulated in the kidney may be
higher than those in the blood. Thus, low blood concentra-
tions of suramin may be sufficient for achieving a therapeutic
effect, and a one-dose regimen may offer a therapeutic
concentration in the kidney. In this study, we observed that
0.1–1 mg/kg of suramin was sufficient for the promotion of
kidney function recovery in mice and that 10 mg/kg was not
toxic. This dose is much lower than that used for suramin
treatment of human tumors (10–30 mg/kg).46,47 In addition,
although our data indicate that delayed administration of
suramin up to 24 h after ischemic injury accelerated the
return of renal function, this therapeutic window may not
be limited to 24 h after injury. Rather, suramin also may be
effective at later time points after the initial renal insult. Thus,
suramin efficacy needs to be measured at other time points,
such as 48 and 72 h after injury, to learn the time window that
allows suramin to achieve the therapeutic outcome.
In summary, extended delayed administration of suramin,
when serum creatinine levels were maximal, markedly
promoted recovery of renal function induced by I/R injury.
Suramin activity was associated with inhibition of apoptosis,
attenuation of inflammation, and promotion of tubular cell
proliferation. These broad actions of a single, low-dose of
suramin are clinically important because most patients with
AKI do not receive preemptive treatments. Therefore,
suramin may have significant clinical implications as a
therapeutic agent.
MATERIALS AND METHODS
Chemicals and reagents
Suramin and the naphthol AS-D chloroacetate esterase kit were
purchased from Sigma-Aldrich (St. Louis, MO, USA). An antibody
against PCNA was obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). Antiactive caspase-3 and anti-phospho-
histone H3 antibodies were purchased from Cell Signaling
Technology (Cambridge, MA, USA). A TUNEL assay kit was obtained
from Roche (Nutley, NJ, USA). RB2, PPADS, and MRS2179 were
purchased from Tocris Bioscience (Ellisville, MO, USA).
Mouse model of renal I/R injury and administration of
suramin
C57BL/6 mice were used for this experiment. Male mice (B25 g)
were subjected to bilateral I/R injury to produce ARF as described by
Kelly et al.48 Briefly, mice were anesthetized with pentobarbital
(65 mg/kg) and placed on a sterile disposable towel over a warming
pad. A midline incision was made, and the renal artery and vein
were isolated from surrounding tissue and then occluded with a
nontraumatic vascular clamp (85 g pressure; Roboz Surg
Instruments) for 26 min. In the sham group, the renal pedicles
were isolated, but no clamps were applied. At the end of the
ischemic period, the vascular clamps were removed and the kidneys
observed for 3–5 min to document reflow. Blood was collected at 24
and 48 h after I/R injury for measurement of BUN and serum
creatinine.
At 24 h after ischemia, a range of suramin doses (0.001, 0.01, 0.1,
1, and 10 mg/kg) were administered to mice through the penis vein.
Mice were randomized into groups with 4–6 animals in each group
as follows: (1) sham injury with vehicle (saline) for 48 h; (2) I/R
injury with vehicle for 24 and 48 h; (3) I/R injury with suramin
(0.001, 0.01, 0.1, 1, and 10 mg/kg) administered at 24 h after I/R.
Because other studies and our preliminary data revealed that a single
dose of suramin is not toxic at 10 mg/kg,49 we did not include sham
injury groups with a variety of suramin doses. Also, because suramin
has a long half-life (421 days) and accumulates in the kidney,43,50
only a single dose was given.
Assessment of renal function
Renal function was monitored by measuring serum creatinine and
BUN at the MUSC Clinical Laboratory.
Histology and immunohistochemistry
Renal tissues were fixed in 4.5% buffered formalin, dehydrated, and
embedded in paraffin. For general histology, sections were stained
with hematoxylin/eosin. For immunofluorescent staining, primary
antibodies against PCNA (1:200), phospho-histone H3 at serine 10
(1:100) or active caspase-3 (1:100) and fluorescent-conjugated
secondary antibodies (1:200) were applied to the sections.
Examination and scoring of sections from each kidney (n¼ 4–6
for each condition) were carried out in a blinded fashion by a renal
pathologist (L. Wang). Morphological damage (epithelial necrosis,
luminal necrotic debris, and tubular dilation) in 3–4 sections per
kidney and 10–12 fields per section were quantified using the
following scale: none¼ 0; o10%¼ 1; 11–25%¼ 2; 26–75%¼ 3; and
475%¼ 4).
Assessment of renal inflammation
To quantify leukocyte infiltration, sections were stained with
naphthol AS-D chloroacetate esterase, which identifies neutrophils
and monocytes. A total of 25 fields of esterase-stained sections
(original magnification  20) were examined for quantitation of
leukocytes. Leukocyte infiltration was expressed as the number of
cells per field.
In situ TUNEL assays
TUNEL staining was used to detect DNA strand breaks. Fixed
kidney sections obtained 48 h after renal injury were deparaffinized
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in xylene and rehydrated through a graded ethanol series to water. In
situ labeling of DNA strand breaks was performed with TUNEL
staining using a commercially available in situ cell death detection
kit, according to the instructions provided by the manufacturer. The
number of TUNEL-positive nuclei per field was evaluated in five
fields per section and five sections per kidney.
Isolation and culture of renal proximal tubules
Isolation and culture of renal proximal tubules were performed as
described previously.51 Female New Zealand White rabbits
(1.5–2.5 kg) were purchased from Myrtle’s Rabbitry (Thompson
Station, TN, USA). RPTCs were isolated using the iron oxide
perfusion method and grown in six-well tissue culture dishes under
improved conditions. The culture medium was a 1:1 mixture of
Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium (without
glucose, phenol red, or sodium pyruvate) supplemented with 15 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, 2.5 mM
L-glutamine, 1 mM pyridoxine HCl, 15 mM sodium bicarbonate, and
6 mM lactate. Hydrocortisone (50 mM), selenium (5 ng/ml), human
transferrin (5mg/ml), bovine insulin (10 nM), and L-ascorbic acid-2-
phosphate (50 mM) were added daily to fresh culture medium. On
day 2 after plating, RPTC were treated with diluent, suramin, RB
(100 mm), PPADS (30mm), or MRS2179 (10 mm) for 48 h and
harvested for cell-cycle analysis.
Cell cycle analysis
Cell-cycle analysis was performed using flow cytometry as
previously described.52 Cells were harvested and stained with
propidium iodide, and the number of cells in the S-phase of the
cell cycle was determined.
Statistical analyses
The data were analyzed with one-way ANOVA plus the Dunnett post
hoc multiple-comparisons test for comparisons of mean values
among multiple treatment groups. Po0.05 was considered a
statistically significant difference among mean values.
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